Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
Status:
Withdrawn
Trial end date:
2019-07-17
Target enrollment:
Participant gender:
Summary
The purpose of this proof of concept, pilot study is to determine whether the unique
combination of the human immunodeficiency virus (HIV) co-receptor antagonist, Maraviroc, and
the mammalian target of rapamycin (mTOR) inhibitor, Sirolimus, in HIV-infected kidney
transplant recipients has an impact on chemokine receptor 5 (CCR5) density, the
HIV-reservoir, or rejection of the transplanted kidney. 15 HIV-infected kidney transplant
recipients will be recruited and their immunosuppressant regimen will be changed to include
an mTOR inhibitor (such as Sirolimus) unless they are already on one. In addition, Maraviroc
will be added to their HIV regimen, unless they are already on Maraviroc. Blood will be taken
to measure markers of the HIV reservoir, their CCR5 density and expression, and immune
activation.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore